Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LODESTAR: Low Dose Spironolactone and Chlorthalidone in CKD
NCT07645300Phase 2Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2026
- Primary completion
- Mar 2032
- Countries
- 1
01
Overview
A Phase 2 trial of spironolactone, chlorthalidone in hypertension (HTN), sponsored by VA Office of Research & Development. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
spironolactonechlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07645300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645300.